Latest Articles
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Jan. 5, 2026, 1:12 p.m.
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy - Targeted Oncology
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy Targeted Oncology
Published: Jan. 5, 2026, 1:07 p.m.
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer - Targeted Oncology
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer Targeted Oncology
Published: Dec. 23, 2025, 2:07 p.m.
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Dec. 22, 2025, 1:15 p.m.
Oncology Nurse Turns Pain Into Purpose As End Endo 5K Leader - Endometriosis Foundation of America
Oncology Nurse Turns Pain Into Purpose As End Endo 5K Leader Endometriosis Foundation of America
Published: Nov. 25, 2025, 6:57 p.m.
Oncology Nurse Who Had Stage IV Endometriosis and a Hysterectomy at 25 Leads End Endo 5K Participants to New Record - Endometriosis Foundation of America
Oncology Nurse Who Had Stage IV Endometriosis and a Hysterectomy at 25 Leads End Endo 5K Participants to New Record Endometriosis Foundation of America
Published: Nov. 25, 2025, 6:57 p.m.
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data - CancerNetwork
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data CancerNetwork
Published: Nov. 16, 2025, 5:11 p.m.
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology
Published: Nov. 12, 2025, 7:08 p.m.
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? ts2.tech
Published: Nov. 3, 2025, 2:12 p.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Oct. 27, 2025, 3:49 p.m.
Link copied to clipboard!